Adial Pharmaceuticals Inc

10-Year Study

ADIL.US · Healthcare · US · Common Stock

Executive Summary: Adial Pharmaceuticals Inc has compounded at -57.3% annually over the last 10 years, with a maximum drawdown of 100.0% and an annualized volatility of 302.7%.

1Y CAGR
-75.7%
3Y CAGR
-76.4%
5Y CAGR
-71.9%
10Y CAGR
-57.3%

History & Riski10-year historical performance analysis including CAGR, Max Drawdown, Sharpe & Sortino ratios, annual returns, and rolling volatility — all computed from daily market data.

10-Year Growth of $10,000

Max DrawdownMax DrawdownThe largest peak-to-trough decline in the asset's value over the measurement period.Click for full definition →
100.0%
Sharpe RatioSharpe RatioRisk-adjusted return: how much excess return you earn per unit of total risk (volatility).Click for full definition →
-0.30
Sortino RatioSortino RatioLike Sharpe, but only penalizes downside volatility — a more accurate risk measure for asymmetric return distributions.Click for full definition →
-0.71
Ann. VolatilityAnnualized VolatilityThe annualized standard deviation of an asset's returns — a measure of how much prices fluctuate.Click for full definition →
107.3%
Best YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2021 · +58.8%
Worst YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2022 · -92.0%
% Positive Years% Positive YearsThe percentage of calendar years in the measurement period where the asset delivered a positive return.Click for full definition →
13%

Annual Returns

Rolling 12-Month Returns

Rolling 12-Month Annualised Volatility

Historical Drawdowns

Monthly Returns

Monthly Returns Heatmap

YearJanFebMarAprMayJunJulAugSepOctNovDecAnn.
2026-3.2-52.5-29.2-14.055.824.2——————-45.8%
2025-17.8-5.4-19.28.8-0.7-55.944.3-12.9-7.0-1.1-10.3-29.8-78.2%
2024-38.778.9-34.827.8-14.7-20.7-9.6-5.71.80.10.01.0-45.7%
2023120.9-7.4-20.5-1.6-23.7-20.854.2-45.4-36.5-30.613.5-15.1-65.4%
2022-23.0-1.0-2.4-29.9-10.66.3-51.5-17.4-34.8-15.7-8.5-20.3-92.0%
202126.516.7-3.6-9.112.33.2-4.368.04.6-25.2-13.4-2.958.8%
2020-24.5-20.9-9.714.18.9-13.915.8-14.361.6-22.033.9-27.0-29.5%
20196.8-34.0-5.0-23.6-29.4-9.27.1-8.3-8.52.6-6.566.2-52.9%
2018———————-22.9-11.6-30.5102.733.328.0%

Risk X-RayiA 19-factor macroeconomic risk decomposition showing exactly which market forces (equity beta, rates, inflation, credit, commodity, crypto) drive this asset's volatility. Powered by multivariate regression against daily factor returns.

Risk Profile Insight: This asset has an estimated annualized volatility of 302.7%. The dominant macroeconomic risk driver is SHV.US, accounting for 90.3% of variance. Idiosyncratic stock-specific factors contribute 5.0%.

10-Year Historical Price Series (Growth of $10,000)
DateSimulated Value
2018-07-0110000
2018-08-017710.25
2018-09-016812.5
2018-10-014736
2018-11-019600
2018-12-0112800
2019-01-0113675
2019-02-019025
2019-03-018575
2019-04-016550
2019-05-014625
2019-06-014200
2019-07-014500
2019-08-014125
2019-09-013775
2019-10-013875
2019-11-013625
2019-12-016025
2020-01-014550
2020-02-013600
2020-03-013250
2020-04-013707.75
2020-05-014037.75
2020-06-013474.9999999999995
2020-07-014025.0000000000005
2020-08-013449.9999999999995
2020-09-015575
2020-10-014350
2020-11-015825
2020-12-014250
2021-01-015375
2021-02-016274.999999999999
2021-03-016050
2021-04-015500
2021-05-016175.000000000001
2021-06-016375
2021-07-016100
2021-08-0110250
2021-09-0110725
2021-10-018025
2021-11-016949.999999999999
2021-12-016750
2022-01-015200
2022-02-015150
2022-03-015024.999999999999
2022-04-013525
2022-05-013150
2022-06-013350
2022-07-011625
2022-08-011342.0000000000002
2022-09-01875
2022-10-01737.5
2022-11-01674.7476
2022-12-01537.5
2023-01-011187.5
2023-02-011100
2023-03-01875
2023-04-01861.2499999999999
2023-05-01657.5
2023-06-01520.5
2023-07-01802.5
2023-08-01438
2023-09-01277.99
2023-10-01193
2023-11-01219
2023-12-01185.99999999999997
2024-01-01114.00999999999999
2024-02-01204.00000000000003
2024-03-01133
2024-04-01170
2024-05-01145
2024-06-01115
2024-07-01104
2024-08-0198.1
2024-09-0199.9
2024-10-01100
2024-11-01100
2024-12-01101
2025-01-0183
2025-02-0178.5
2025-03-0163.42
2025-04-0169
2025-05-0168.5
2025-06-0130.22
2025-07-0143.61
2025-08-0138
2025-09-0135.35
2025-10-0134.96
2025-11-0131.36
2025-12-0122
2026-01-0121.3
2026-02-0110.12
2026-03-017.16
2026-04-016.16
2026-05-019.6
2026-06-0111.92
Annual Return Matrix
YearAnnual Return
2019-0.529296875
2020-0.29460580912863066
20210.588235294117647
2022-0.9203703703703704
2023-0.653953488372093
2024-0.456989247311828
2025-0.7821782178217822
2026-0.45818181818181813
Total Factor Risk
3.0269998234810633
VTI.US Exposure
0.020404754515277877
VEA.US Exposure
0.00016847152338640554
VWO.US Exposure
0.0007041307186087246
QQQ.US Exposure
-0.00012463701873610978
VTV.US Exposure
0.005507893087706184
IJR.US Exposure
0.00005316529355095595
QUAL.US Exposure
0.0007216032671781702
SHV.US Exposure
0.9032031648372326
TLT.US Exposure
0.0004249318225789966
LQD.US Exposure
0.00507294039086717
HYG.US Exposure
0.00039250553402755674
GLD.US Exposure
0.00026643866522214736
USO.US Exposure
0.004584317050247748
VNQ.US Exposure
0.0018519599586077637
BTC-USD.CC Exposure
0.002126849499687415
CPER.US Exposure
0.0036382509011417636
VIX.INDX Exposure
-0.00011100253871416597
UUP.US Exposure
0.0003007987746429005
TIP.US Exposure
0.0006944778040655017
Idiosyncratic Exposure
0.05011898591342035
Value Score
50
Growth Score
50
Profit Score
37.5
Health Score
23.6
Yield Score
0
Moat Score
40

Factor Risk Decomposition

Share of annualised volatility attributable to each macro factor.

Total Est. Vol
302.7%

FundamentalsiCompany financial health metrics: P/E valuation, dividend yield, Piotroski F-Score (9-point profitability signal), Altman Z-Score (bankruptcy risk proxy), and a radar chart across 6 fundamental dimensions. Note: ETFs may show N/A for some metrics.

Fundamental Dimensions

Core Valuation

P/E Ratio (TTM)P/E RatioPrice-to-Earnings ratio — the market price of a stock divided by its earnings per share, a key valuation measure.Click for full definition →N/A
Forward P/EForward P/E RatioA valuation metric that compares the current stock price to estimated future earnings per share.Click for full definition →No estimate availableN/A
Dividend YieldDividend YieldAnnual dividend paid per share divided by the current share price — expressed as a percentage income return.Click for full definition →0.00%
Squeeze RiskShort Squeeze RiskA situation where a sharp rise in the price of a stock forces short sellers to buy shares to cover their positions, further driving up the price.Click for full definition →Low
Market Cap$2.6M
Piotroski F-ScorePiotroski F-ScoreA 9-point scoring system evaluating a company's financial strength across profitability, leverage, and operating efficiency.Click for full definition →
9-point profitability signal
0.0/ 9
Weak
Altman Z-ScoreAltman Z-ScoreA bankruptcy prediction model that combines 5 financial ratios into a single score indicating financial distress risk.Click for full definition →
Bankruptcy risk proxy
1.18
Distress Zone
Income Simulation

Based on $10,000 initial investment.

Total Income Generated
$0
Avg Yield on Cost
0.00%

Momentum & MacroiPrice momentum indicators: distance from 50/200-Day SMA, 52-Week High proximity, Golden Cross trend signal, RSI momentum gauge, Fibonacci retracement levels, and Beta (market sensitivity).

vs 50-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
+63.6%
Above/below 50-day moving average
vs 200-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
-43.0%
Above/below 200-day moving average
vs 52-Week High52-Week HighThe highest price an asset reached in the past 52 weeks — a key reference for momentum and valuation context.Click for full definition →
81.1% from high
Distance from 52-week high
BetaBetaA measure of an asset's sensitivity to broad market movements relative to a benchmark (e.g. S&P 500).Click for full definition →
1.24
Market sensitivity coefficient
Trend SignalGolden Cross & Death CrossTechnical chart patterns that occur when a short-term moving average crosses over a long-term moving average.Click for full definition →
✦ Death Cross
Bearish — 50 SMA below 200 SMA
RSI (14-Day)Relative Strength Index (RSI)A momentum oscillator that measures the speed and change of price movements to identify overbought or oversold conditions.Click for full definition →
65
OversoldNeutralOverbought
Neutral
Fibonacci LevelsFibonacci RetracementTechnical levels based on mathematical ratios that indicate potential support and resistance areas.Click for full definition →
38.2% retracement-70.9%
50.0% retracement-65.2%
61.8% retracement-56.5%
% distance of current price from each 52-week Fibonacci support level.

Compare this AssetiRun a head-to-head backtest and risk analysis against similar assets.

ADIL.USvsBTSG.US

Compare Adial Pharmaceuticals Inc vs BrightSpring Health Services, Inc. Common Stock

ADIL.USvsBTSGU.US

Compare Adial Pharmaceuticals Inc vs BrightSpring Health Services, Inc. Tangible Equity Unit

ADIL.USvsAPGE.US

Compare Adial Pharmaceuticals Inc vs Apogee Therapeutics, Inc. Common Stock

Frequently Asked Questions & Methodology

Is Adial Pharmaceuticals Inc a high-risk investment?

Adial Pharmaceuticals Inc (ADIL.US) has an annualized volatility of 302.7% and experienced a maximum drawdown of 100.0% over the last 10 years. Its primary macro risk driver is SHV.US.

What is the 10-year return of ADIL.US?

Over the past 10 years, ADIL.US has generated a Compound Annual Growth Rate (CAGR) of -57.3%. It has had a positive return in 13% of the years measured.

Data Methodology & Trust

The risk and return information on this page is pre-calculated mathematically using daily market data spanning a 10-year period. Fundamentals (such as P/E Ratio, Market Cap, and Dividend Yield) represent trailing averages and may not immediately reflect real-time live market fluctuations. Advanced scoring models like the Piotroski F-Score and Altman Z-Score are proxies applied to publicly available trailing-twelve-month financial statements and may not account for recent off-balance-sheet events, qualitative company shifts, or sector-specific capital structures. Macroeconomic factor exposures are estimated via multivariate regression against standard market indices. This data is provided for quantitative insight and backtesting research, and should not be misconstrued as tailored financial advice.

Run a Full Backtest on Adial Pharmaceuticals Inc

stresstest.pro lets you simulate DCA vs Lump Sum, Monte Carlo projections, portfolio optimisation, and more — all in seconds.

Start a Free Backtest